Comprehensive Review on Ayurvedic Formulations and Herbal Medicines for Treatment of Rheumatoid Arthritis

Farha Sultana;  ; Bhavika Arora; Sandeep Arora; Rakesh K. Sindhu; Farha Sultana;  ;  ;  ;

doi:10.51201/jusst/21/07218

Comprehensive Review on Ayurvedic Formulations and Herbal Medicines for Treatment of Rheumatoid Arthritis

Journal of University of Shanghai for Science and Technology ◽

10.51201/jusst/21/07218 ◽

2021 ◽

Vol 23 (07) ◽

pp. 772-790

Author(s):

Farha Sultana ◽

◽

Bhavika Arora ◽

Sandeep Arora ◽

Rakesh K. Sindhu ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Joint Destruction ◽

Herbal Medicines ◽

Inflammatory Disorder ◽

Infectious Agents ◽

Genetic Changes ◽

First Choice ◽

Environmental Agents ◽

Herbal Therapies ◽

Cartilage Erosion

Rheumatoid arthritis, an autoimmune inflammatory disorder is characterized by progressive cartilage erosion leading to joint destruction, pain, stiffness, and swelling. Although the etiology of the disease is unknown, genetic changes due to factors such as environmental agents, immune response towards infectious agents influence rheumatoid arthritis. Earlier NSAIDs were the first choice of drugs for the treatment of disease but due to having certain side effects and limitations, herbal therapies which possess higher efficacy and safety are now in demand. There are hundreds of plants that have phytoconstituents that exhibit anti-inflammatory activity. A combination of plants is used to make polyherbal formulations that act synergistically to give anti-arthritic activity. The review is about the botanicals and traditional formulations which have been clinically tested for the treatment of Rheumatoid arthritis.

Download Full-text

Dysregulation of lncRNAs in Rheumatoid Arthritis: Biomarkers, Pathogenesis and Potential Therapeutic Targets

Frontiers in Pharmacology ◽

10.3389/fphar.2021.652751 ◽

2021 ◽

Vol 12 ◽

Author(s):

Chenggui Miao ◽

Liangliang Bai ◽

Yaru Yang ◽

Jinling Huang

Keyword(s):

Rheumatoid Arthritis ◽

Epigenetic Modification ◽

Joint Destruction ◽

Research Progress ◽

Unknown Etiology ◽

Signal Pathways ◽

Cartilage Erosion ◽

Chronic Autoimmune Disease ◽

Fibroblast Like Synoviocytes

Rheumatoid arthritis (RA) is a chronic autoimmune disease of unknown etiology, mainly manifested by persistent abnormal proliferation of fibroblast-like synoviocytes (FLSs), inflammation, synovial hyperplasia and cartilage erosion, accompanied by joint swelling and joint destruction. Abnormal expression or function of long noncoding RNAs (lncRNAs) are closely related to human diseases, including cancers, mental diseases, autoimmune diseases and others. The abnormal sequence and spatial structure of lncRNAs, the disorder expression and the abnormal interaction with the binding protein will lead to the change of gene expression in the way of epigenetic modification. Increasing evidence demonstrated that lncRNAs were involved in the activation of FLSs, which played a key role in the pathogenesis of RA. In this review, the research progress of lncRNAs in the pathogenesis of RA was systematically summarized, including the role of lncRNAs in the diagnosis of RA, the regulatory mechanism of lncRNAs in the pathogenesis of RA, and the intervention role of lncRNAs in the treatment of RA. Furthermore, the activated signal pathways, the role of DNA methylation and other mechanism have also been overview in this review.

Download Full-text

Smart Drug-Delivery Systems in the Treatment of Rheumatoid Arthritis: Current, Future Perspectives

10.5772/intechopen.99641 ◽

2021 ◽

Author(s):

Largee Biswas ◽

Vikas Shukla ◽

Vijay Kumar ◽

Anita Kamra Verma

Keyword(s):

Rheumatoid Arthritis ◽

Drug Delivery ◽

Drug Delivery Systems ◽

Folate Receptor ◽

Joint Destruction ◽

Delivery Systems ◽

Inflammatory Disorder ◽

Emerging Trends ◽

Smart Drug ◽

Smart Drug Delivery

Rheumatoid arthritis (RA) is a progressive autoimmune inflammatory disorder characterized by cellular infiltration in synovium causing joint destruction and bone erosion. The heterogeneous nature of the disease manifests in different clinical forms, hence treatment of RA still remains obscure. Treatments are limited owing to systemic toxicity by dose-escalation and lack of selectivity. To overcome these limitations, Smart drug delivery systems (SDDS) are under investigation to exploit the arthritic microenvironment either by passive targeting or active targeting to the inflamed joints via folate receptor, CD44, angiogenesis, integrins. This review comprehensively deliberates upon understanding the pathophysiology of RA and role of SDDSs, highlighting the emerging trends for RA nanotherapeutics.

Download Full-text

Rheumatoid Arthritis Management for General Internists

Canadian Journal of General Internal Medicine ◽

10.22374/cjgim.v8i0.104 ◽

2016 ◽

Vol 8 ◽

Author(s):

Mitchell Uh MD FRCPC ◽

David Collins MD FRCPC ABIM

Keyword(s):

Rheumatoid Arthritis ◽

Interstitial Lung Disease ◽

Lung Disease ◽

Joint Destruction ◽

Morbidity And Mortality ◽

Inflammatory Disorder ◽

General Internists ◽

Canadian Population ◽

Increased Risk ◽

Significant Disability

Rheumatoid arthritis (RA) is a chronic systemic inflammatory disorder that causes progressive joint destruction, deformity, and significant disability. In addition to arthritis, RA is associated with numerous extra-articular features with attendant morbidity and mortality. These include but are not limited to ocular inflammation, interstitial lung disease, pleuropericardial disease, vasculitis, accelerated atherosclerosis, and increased risk of lymphoma. The prevalence of RA in the Canadian population is approximately 1%.

Download Full-text

Rheumatoid arthritis: a joint venture

South African General Practitioner ◽

10.36303/sagp.2020.1.5.0050 ◽

2020 ◽

pp. 193-195

Author(s):

E Potgieter

Keyword(s):

Rheumatoid Arthritis ◽

Joint Venture ◽

Functional Disability ◽

Joint Destruction ◽

Developed Countries ◽

Western World ◽

Inflammatory Disorder ◽

Full Time ◽

Industrialised Countries ◽

Full Time Employment

Rheumatoid arthritis (RA) is a chronic auto-immune inflammatory disorder, usually affecting the joints. Its prevalence is estimated at 0.3–1% in industrialised countries and areas of urban living. RA leads to functional disability, significant pain and joint destruction, and subsequent loss of income: in developed countries half of people diagnosed with RA are unable to sustain full-time employment ten years after diagnosis. It also carries substantial cardiovascular risk if inadequately treated. RA is possibly the largest cause of treatable disability in the Western World. The exact prevalence of RA in South Africa is currently not known, but its significant impact is compounded by frequent late diagnoses and a scarcity of treating specialists.

Download Full-text

AYURVEDIC TREATMENT OF RHEUMATOID ARTHRITIS: A CASE STUDY

International Journal of Research in Ayurveda and Pharmacy ◽

10.7897/2277-4343.12011 ◽

2021 ◽

Vol 12 (1) ◽

pp. 1-4

Author(s):

Neha Rawat ◽

Vishal Aggarwal ◽

Rakesh Roushan

Keyword(s):

Rheumatoid Arthritis ◽

Joint Destruction ◽

Joint Stiffness ◽

Metacarpophalangeal Joint ◽

Modern Medicine ◽

The Body ◽

Ayurvedic Medicine ◽

Inflammatory Disorder ◽

Chronic Inflammatory Disorder ◽

Ayurvedic Drugs

Pain makes us conscious for the presence of the injurious agent and that is why we seek removal of the injurious agent by appropriate measures. Rheumatoid arthritis (RA) is corelated with aamvata in Ayurved. Rheumatoid arthritis is basically an autoimmune chronic inflammatory disorder that mainly affects the symmetrical metacarpophalangeal joint and more than two to three proximal interphalangeal small joints of the body. This disease is commonly found in females as compared to males. The female male ratio is 3:1. Prevalence of Rheumatoid arthritis increases with age, with 5% of women and 2% of men over 55 years being affected. Rheumatoid arthritis is rare in men under the age of 45, where there is 6:1 female surplus. It’s a very painful disease which usually cause tender, swelling and inflammation in joints. Joint stiffness worse in the morning and remain for more than one hour. Chronic inflammation, granuloma formation and joint destruction is commonly seen. Fatigue, fever, weight loss, irritation and depression are also the most common non-articular symptoms. A satisfactory treatment is available in Ayurvedic medicine for this disorder. Various Ayurvedic drugs have been proved useful for these manifestations. This case report is a classic case of Rheumatoid arthritis, which was treated for six months under the name of aamvata with Ayurvedic drugs. The patient was on modern medicine and we efficaciously exchange him from conventional modern medicine to ayurvedic medicine.

Download Full-text

Deciphering Role of Cytokines for Therapeutic Strategies Against Rheumatoid Arthritis

Current Drug Targets ◽

10.2174/1389450121666201027124625 ◽

2020 ◽

Vol 21 ◽

Author(s):

Gaurav Doshi ◽

Ami Thakkar

Keyword(s):

Rheumatoid Arthritis ◽

Joint Destruction ◽

Therapeutic Agents ◽

Therapeutic Strategies ◽

Inflammatory Disorder ◽

Irreversible Damage ◽

Pharmacological Agents ◽

Symmetric Pattern ◽

Novel Therapeutic Strategies

: Rheumatoid Arthritis (RA) is a systemic, chronic, autoimmune, inflammatory disorder which affects of the both large and small synovial joints in a symmetric pattern. RA initiates as painful inflammation of the joints leading to stiffness of joint, joint destruction and further worsens the condition causing permanent irreversible damage to the joints making them physically disabled. Across the globe, there are around 1.2 million cases of RA reported. Inspite of various available therapeutic and pharmacological agents against RA, none of the treatment assure complete cure. Understanding the in depthrole of cytokines and interleukins in disease pathogenesis of RA could help in exploiting them for developing novel therapeutic strategies against RA. This review provides insights into pathogenesis of RA and gives a brief overview of cytokines which play an important role in the progression of the disease. We have also discussed possible role of interleukins in context of RA which could help future researchers to explore them for identifying new therapeutic agents.

Download Full-text

Effectiveness of Methotrexate and Salfasalazine Alone Versus Methotrexate and Sulphasalazine Combination in the Treatment of Rheumatoid Arthritis

Bangladesh Journal of Medicine ◽

10.3329/bjmed.v26i2.25451 ◽

2015 ◽

Vol 26 (2) ◽

pp. 67-75

Author(s):

Md Abdul Baset ◽

Bidhu Bhusan Das ◽

Devendra Nath Sarkar ◽

Mainuddinin Ahmed ◽

Md Ismail Hossain ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Joint Destruction ◽

Inflammatory Disorder ◽

Group Iii ◽

Das 28 ◽

Group I ◽

The Mean ◽

Disease Modifying ◽

Group Ii ◽

The Difference

Background: Rheumatoid arthritis is a chronic, autoimmune, inflammatory disorder of unknown aetiology that is characterized by symmetric synovitis and the propensity to cause joint destruction, disability and premature death. Disease-modifying anti-rheumatic drugs (DMARDs) slow the natural course of the disease, reduce joint damage and pain, and retard loss of function and disability. Disease modifying agents should be started as early as possible. A number of studies demonstrating the effectiveness of combinations of DMARDs in early RA.Methods: This is a comparative descriptive type of study was conducted in the Department of Medicine, Rangpur Medical College and Hospital, Rangpur & Medicine Specialists Chambers, Rangpur, over a period of 2 (two) years from July 2010 to June 2012 on newly diagnosed RA patients on the basis of ACR criteria. The 30 patients were divided into 3 groups. Group I got MTX, Group II got SSZ and Group III got MTX & SSZ. Purposive consecutive sampling method was employed. The objective of the study was to evaluate the outcome of patients of rheumatoid arthritis treated with MTX or SSZ alone versus MTX and SSZ in combination. The primary outcome measure was change in DAS28.Results: The mean DAS 28 score baseline was found 7.23±0.44 in group I, 7.29±0.39 in group II and 7.86±0.41 in group III. The mean DAS 28 score end of the study was 4.24±0.39 in group I, 4.85±0.54 in group II and 3.08±0.36 in group III. The difference was statistically significant (P<0.001) among the three groups. There is no toxicity found in any group. Regarding side effects, the difference was not statistically significant (P>0.05) among the three groups.Conclusion : This study suggests that the mean changes in the DAS28 score significantly lower in those who received combination therapy compared with those who received either MTX or SSZ alone during one year follow up.Bangladesh J Medicine Jul 2015; 26 (2) : 67-75

Download Full-text